Ion-sensitive in situ hydrogels of natamycin bilosomes for enhanced and prolonged ocular pharmacotherapy: in vitro permeability, cytotoxicity and in vivo evaluation
Source abstract
Abstract
Delivery of therapeutic molecules into the deeper ocular compartments is mainly hampered by short precorneal residence and limited transmembrane permeability of topically administered drugs. Hence, the current study was undertaken to fabricate the ion-sensitive in situ gels of natamycin (NT) bilosomes (NB) for efficient ocular delivery. The effect of cholesterol and sodium taurocholate proportion on the properties of the bilosomes were studied and the formulation with better physicochemical properties was optimized and utilized to derive the in situ gelling system (IG). The impact of type/composition of gelling agent on the formation and characteristics of the hydrogel was investigated. The hydrogel formed from IG with 0.3% w/v gellan gum showed optimal viscoelastic and adhesive characteristics. The ocular safety and cytocompatibility of NB and its IG was confirmed by corneal histology and in vitro cytotoxicity evaluation. A 6- to 9-fold enhancement in the transcorneal flux of NB demonstrated efficient ocular penetration of bilosomes. Moreover, the superior mean dose normalized NT levels in the ocular tissues of rabbits treated with optimized NB and IG illustrated the effectiveness of bilosomes loaded ion-sensitive in situ hydrogels as a potential platform for the improved and prolonged ocular pharmacotherapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Advanced Drug Delivery Systems · Ocular Infections and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi
Department of Ophthalmology, The University of Tennessee Health Science Center, Hamilton Eye Institute
Department of Pharmaceutics, Faculty of Pharmacy, Mansoura University
Research Institute of Pharmaceutical Sciences, The University of Mississippi
Funding
National Eye Institute · National Institutes of Health
References (53)
Show source-provided references
1. 10.1167/iovs.13-1370710.1167/iovs.13-13707 ↗
2. 10.1016/j.addr.2006.07.02710.1016/j.addr.2006.07.027 ↗
3. 10.5497/wjp.v2.i2.4710.5497/wjp.v2.i2.47 ↗
4. 10.1586/17512433.1.1.14510.1586/17512433.1.1.145 ↗
5. 10.1016/j.addr.2017.09.00810.1016/j.addr.2017.09.008 ↗
6. 10.1080/10717544.2016.125600010.1080/10717544.2016.1256000 ↗
7. 10.1016/j.xphs.2017.07.01710.1016/j.xphs.2017.07.017 ↗
8. 10.15406/japlr.2016.02.0002210.15406/japlr.2016.02.00022 ↗
9. 10.3109/21691401.2013.85601610.3109/21691401.2013.856016 ↗
10. 10.1080/21691401.2017.134977910.1080/21691401.2017.1349779 ↗
11. 10.2174/187221130966615072410122710.2174/1872211309666150724101227 ↗
12. 10.1016/j.ijpharm.2011.03.04210.1016/j.ijpharm.2011.03.042 ↗
13. 10.4103/2230-973X.10003610.4103/2230-973X.100036 ↗
14. 10.1021/mp500332m10.1021/mp500332m ↗
15. 10.1016/j.ijpharm.2017.06.04210.1016/j.ijpharm.2017.06.042 ↗
16. 10.1016/j.ejpb.2016.10.01510.1016/j.ejpb.2016.10.015 ↗
17. 10.1016/j.jconrel.2017.01.01210.1016/j.jconrel.2017.01.012 ↗
18. 10.1038/srep4422910.1038/srep44229 ↗
19. 10.1080/21691401.2017.129064710.1080/21691401.2017.1290647 ↗
20. 10.1016/j.ijpharm.2012.04.06310.1016/j.ijpharm.2012.04.063 ↗
21. 10.4103/2231-4040.10749510.4103/2231-4040.107495 ↗
22. 10.4103/2230-973X.17648810.4103/2230-973X.176488 ↗
23. 10.1016/j.ejps.2017.04.01310.1016/j.ejps.2017.04.013 ↗
24. 10.1016/j.xphs.2016.09.01910.1016/j.xphs.2016.09.019 ↗
25. 10.1016/j.jddst.2017.03.00510.1016/j.jddst.2017.03.005 ↗
26. 10.1016/j.drudis.2016.03.01310.1016/j.drudis.2016.03.013 ↗
27. 10.1016/j.ijpharm.2015.03.03310.1016/j.ijpharm.2015.03.033 ↗
28. 10.1016/j.ijpharm.2016.10.00610.1016/j.ijpharm.2016.10.006 ↗
29. 10.1097/00003226-200005000-0001010.1097/00003226-200005000-00010 ↗
30. 10.1080/09205063.2014.95801610.1080/09205063.2014.958016 ↗
31. 10.1016/j.ijpharm.2012.04.06010.1016/j.ijpharm.2012.04.060 ↗
32. Thangabalan B, Kumar PV. Analytical method development and validation of natamycin in eye drop by RP-HPLC. Asian J Pharm Clin Res. 2013;6:134–135.
33. 10.1002/jps.2242210.1002/jps.22422 ↗
34. Nagesh C, Patil M, Chandrashekar S, et al. A novel in situ gel for sustained ophthalmic delivery of ciprofloxacin hydrochloride and dexamethasone- design and characterization. Der Pharmacia Lett. 2012;4:821–827.
35. 10.1111/ics.1212510.1111/ics.12125 ↗
36. 10.1002/jps.2341710.1002/jps.23417 ↗
37. 10.1007/s11095-008-9729-610.1007/s11095-008-9729-6 ↗
38. 10.1016/j.ijpharm.2011.04.02710.1016/j.ijpharm.2011.04.027 ↗
39. 10.1016/j.bpj.2009.06.02510.1016/j.bpj.2009.06.025 ↗
40. 10.1016/j.ejpb.2011.10.01010.1016/j.ejpb.2011.10.010 ↗
41. 10.2147/IJN.S4448710.2147/IJN.S44487 ↗
42. 10.1016/j.ijpharm.2010.06.03410.1016/j.ijpharm.2010.06.034 ↗
43. 10.3109/08982104.2012.70046010.3109/08982104.2012.700460 ↗
44. 10.2147/IJN.S1991710.2147/IJN.S19917 ↗
45. Inactive ingredient search for approved drug products. Fedral Drug Administration IIG database-2017. Available from: https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
46. 10.9734/JAMPS/2017/3392410.9734/JAMPS/2017/33924 ↗
47. 10.1016/j.foodres.2007.03.00110.1016/j.foodres.2007.03.001 ↗
48. 10.1016/S0008-6215(00)80832-010.1016/S0008-6215(00)80832-0 ↗
49. 10.1016/0169-409X(95)00015-Y10.1016/0169-409X(95)00015-Y ↗
50. 10.3109/08982104.2013.80148910.3109/08982104.2013.801489 ↗
51. 10.1016/j.sjopt.2014.02.00910.1016/j.sjopt.2014.02.009 ↗
52. Barar J, Asadi M, Mortazavi-Tabatabaei SA, et al. Ocular drug delivery; impact of in vitro cell culture models. J Ophthalmic Vis Res. 2009;4:238–252.
53. 10.1016/0378-5173(93)90115-V10.1016/0378-5173(93)90115-V ↗